Insmed Incorporated INSM 深 滬
等待開盤 01-14 09:30:00 美东时间
163.72
-4.000
-2.38%
華盛通- 最 高170.45
- 今 開170.00
- 成交量 374.12万股
- 最 低 162.30
- 昨 收 167.72
- 總市值 345.45亿
- 52周最高 212.75
- 市盈率 靜 --
- 換手率 1.77%
- 52周最低 60.40
- 委 比 -46.52%
- 總股本 2.11亿
- 歷史最高 212.75
- 量 比 1.16
- 振 幅 4.86%
- 歷史最低 2.64
- 每 手 1
- 風險率 46.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股盘后 | Revvity, Inc.涨5.88%，Insmed Incorporated涨5.47%
Revvity, Inc.涨5.88%；Insmed Incorporated涨5.47%；美洲移动涨3.30%
01-13 07:10
Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances
Insmed outlines 2026 outlook, highlighting BRINSUPRI expansion, ARIKAYCE revenue guidance and multiple late-stage clinical milestones across its pipeline.
01-09 23:58
Insmed gains as preliminary 2025 revenue beats consensus
Insmed (INSM) shares traded higher on Friday after the rare disease drug developer announced preliminary unaudited revenue for 2025, exceeding Wall Street forecasts ahead of a presentation at the upco...
01-09 23:54
Insmed shares are trading higher after the company reported FY25 sales results.
Insmed shares are trading higher after the company reported FY25 sales results.
01-09 21:53
Insmed Reports $606M in 2025 Revenue as Sales Jump 67% YoY
Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today provided an
01-09 20:10
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
UBS Maintains Buy on Insmed, Lowers Price Target to $215
UBS analyst Ashwani Verma maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $223 to $215.
01-07 01:59
Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?
Last week's biggest large-cap laggards were Nike, Arm, and Lennar, sliding on weak China demand, analyst downgrades, earnings/CFO headlines, and broader crypto/energy pressure.
2025-12-21 23:01
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Why Is Insmed Stock Falling Thursday?
Insmed shares fall after brensocatib misses Phase 2b CRSsNP endpoints, prompting program discontinuation as analysts remain bullish on other assets.
2025-12-19 01:30
